-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Before February 2021, there is no standard treatment plan for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) treatment.
Cemiplimab (Cemiplimab) is a PD-1 antibody that has been approved for the treatment of advanced cutaneous squamous cell carcinoma and has also shown clinical activity as a first-line monotherapy for non-small cell lung cancer
This article reports the analysis of the main results of cimiprizumab used in patients with locally advanced basal cell carcinoma after HHI treatment.
This is an open-label, multi-center, single-arm Phase 2 clinical trial carried out in 38 medical academic centers in multiple countries, recruiting 18 years of age or older with an ECOG performance status score of 0-1 and histology Patients with diagnosed metastatic basal cell carcinoma (group 1) or locally advanced basal cell carcinoma (group 2) who have progressed after HHI treatment or are resistant to HHI treatment.
Remission at each assessment
Remission at each assessmentFrom November 16, 2017 to January 7, 2019, a total of 84 patients were recruited, all of whom received cimiprizumab treatment.
26 patients (31%) achieved objective remission, 5 (6%) patients achieved complete remission, and 21 (25%) patients achieved partial remission
Progression-free survival
Progression-free survivalForty (48%) patients experienced grade 3-4 adverse events requiring emergency treatment, the most common being hypertension (5%, 4/84) and colitis (5%, 4/84).
In conclusion, cimiprizumab has shown clinically significant anti-tumor activity and acceptable safety in locally advanced basal cell carcinoma patients after HHI treatment , and it is worthy of further study.
Cimiprizumab has shown clinically significant anti-tumor activity and acceptable safety in locally advanced basal cell carcinoma patients after HHI treatment Patients showed clinically significant anti-tumor activity and acceptable safety
Original source:
Original source:Alexxander J Stratigos, et al.
org/10.
1016/S1470-2045(21)00126-1" target="_blank" rel="noopener">Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial in this message
